(Q37973520)

26 August 2017

title

Pioneering designs for recombinant coagulation factors (English)

1 reference

26 August 2017

Stefan Schulte

1

1 reference

26 August 2017

publication date

1 January 2011

1 reference

26 August 2017

1 reference

26 August 2017

volume

128 Suppl 1

1 reference

26 August 2017

page(s)

S9-12

1 reference

Visions in haemophilia care

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970003-8

7 January 2021

Use of albumin fusion technology to prolong the half-life of recombinant factor VIIa

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970003-8

7 January 2021

Sialic acids: carbohydrate moieties that influence the biological and physical properties of biopharmaceutical proteins and living cells

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970003-8

7 January 2021

The versatile MHC class I-related FcRn protects IgG and albumin from degradation: implications for development of new diagnostics and therapeutics.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970003-8

7 January 2021

Development, characterization, and evaluation of a fusion protein of a novel glucagon-like peptide-1 (GLP-1) analog and human serum albumin in Pichia pastoris

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970003-8

7 January 2021

Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970003-8

7 January 2021

Strategies to extend plasma half-lives of recombinant antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970003-8

7 January 2021

Perspective-- FcRn transports albumin: relevance to immunology and medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970003-8

7 January 2021

Pharmaceutical strategies utilizing recombinant human serum albumin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970003-8

7 January 2021

Development of a long-acting insulin analog using albumin fusion technology

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970003-8

7 January 2021

Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970003-8

7 January 2021

Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970003-8

7 January 2021

Effect of albumin fusion on the biodistribution of interleukin-2

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970003-8

7 January 2021

Substantially improved pharmacokinetics of recombinant human butyrylcholinesterase by fusion to human serum albumin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970003-8

7 January 2021

Pharmacokinetics of recombinant activated factor VII (rFVIIa).

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970003-8

7 January 2021

Prolonged in-vivo half-life of factor VIIa by fusion to albumin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970003-8

7 January 2021

Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970003-8

7 January 2021

Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970003-8

7 January 2021

Genetic fusion to albumin improves the pharmacokinetic properties of factor IX.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970003-8

7 January 2021

Half-life extension through albumin fusion technologies

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970003-8

7 January 2021

Effects of genetic fusion of factor IX to albumin on in vivo clearance in mice and rabbits.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970003-8

7 January 2021

VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970003-8

7 January 2021

10.1016/S0049-3848(12)70003-8

Identifiers

DOI

1 reference

26 August 2017

1 reference